Core Viewpoint - Toxin Pharmaceutical (301089.SZ) reported its 2025 semi-annual results, highlighting a total of 22.03 million shares held by institutional investors, representing 17.41% of the company's total equity, with a decline in institutional holding percentage compared to the previous quarter [1] Institutional Holdings - As of August 27, 2025, four institutional investors disclosed their holdings in Toxin Pharmaceutical, with a combined shareholding of 22.03 million shares [1] - The institutional investors include SHENGLIN HOLDING CO. LTD., LUKOIL, UBS AG, and BARCLAYS BANK PLC, with a total institutional holding percentage of 17.41% [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 2.04 percentage points [1] Foreign Investment - One foreign fund, LUKOIL, reduced its holdings compared to the previous quarter, with a decrease of 0.80% [1] - Two new foreign institutions disclosed their holdings during this period, namely UBS AG and BARCLAYS BANK PLC [1]
机构风向标 | 拓新药业(301089)2025年二季度已披露前十大机构持股比例合计下跌2.04个百分点